Search Within

Karthik Nath

  1. "GSK Faculty"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Bone Marrow Transplant (6)
  2. CTCR Scholars (6)
  3. Center for Hematologic Malignancies (6)
  4. Department of Medicine (6)
  5. GME, Medicine (6)
  6. GSK Faculty (6)

More Groups

People
  1. Gunjan Shah (6)
  2. Maria Palomba (6)
  3. Michael Scordo (6)
  4. Miguel-Angel Perales (6)
  5. Parastoo Dahi (6)
  6. Richard Lin (6)

More People

Years
  1. 2023 (3)
  2. 2022 (3)
Publications
  1. Blood (2)
  2. Transplantation and Cellular Therapy (2)
  3. Bone Marrow Transplantation (1)
  4. Nature Medicine (1)
Publishers
  1. American Society of Hematology (2)
  2. Elsevier Inc. (2)
  3. Nature Publishing Group (2)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A reproducible inflammatory biomarker signature identifies non-Hodgkin lymphoma patients at high risk of CAR-T treatment failure across different cohorts
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fei, T.; Fein, J.; Tomas, A. A.; De LaPuerta, M. C.; Dahi, P.; Danylesko, I.; Epstein-Peterson, Z.; Fried, S.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results
    Journal Article

    Park, J. H.; Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G.; Dahi, P.; Lin, R. J.; Scordo, M.; Perales, M. A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy
    Meeting Abstract

    Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Vitamin D insufficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in large B-cell lymphoma
    Journal Article

    Nath, K.; Tomas, A. A.; Flynn, J.; Fein, J. A.; Alperovich, A.; Anagnostou, T.; Batlevi, C. L.; Dahi, P. B.; Fingrut, W. B.; Giralt, S. A.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Vitamin D deficiency is associated with inferior clinical outcomes in patients with large B-cell lymphoma receiving anti-CD19 CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Alarcon Tomas, A.; Flynn, J.; Fein, J. A.; Alperovich, A.; Anagnostou, T.; Batlevi, C. W.; Dahi, P. B.; Fingrut, W.; Giralt, S. A.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save